Search

Abstract Collaborative, situated, and critical methodologies (CSCM) foster processes that provide dialogic and experiential working tools for emerging transdisciplinary agroecologies (TA). CSCM emphasize how local knowledge and practice (praxis) contribute to ensuring care for the common and the personal, safeguarding regenerative processes, actively protecting native seeds, and interweaving biodiverse life systems that support the multifunctional networks of agriculture. This work aimed to understand a selection of collaborative methodologies related to transdisciplinary agroecological processes. We identify these groups: 1. Agroecologies, 2. Popular and own pedagogies, 3. Engaged and transformative pedagogies, 4. Assessment of agroecological sustainability and incidence in public policy, and 5. Participatory marketing and guarantee mechanisms or systems. The CSCM contribute to understanding the relationships, times, meanings, and identities and the heterogeneity of context of each community. Thus, CSCM are essential positions and tools to strengthen the openness and respect required by intercultural spaces of praxis and shared dialogues between different epistemic communities while nourishing TA. TA are complexes of relationships and practices between humans and the diversity of life, and they delve into epistemological, ethical, ontological positions and heterogeneous praxis. These diverse methodological paths characterize the interactions that arise from the heterogeneity of knowledge, experience, and wisdom of interacting epistemic communities crossed by power relations. The shifts in positions and research journeys toward epistemological and environmental justice among biocultural diversities developed by the revised CSCM provide the tools to continue articulating processes, designs, and forms of organization of life networks converging with TA.

The development of skills for oral communication in English is a necessity in today's society, given the importance that the use of this second language has acquired, both for academic training and for development in the workplace. Thus, the objective of this article is to demonstrate the impact generated on the development of oral competence at level A2 by the implementation of communicative activities in students candidates to take the international KEY test. The method included surveys to the group of participants from the High Challenge Language Institute in Riobamba, Ecuador. The results show that, regarding the oral competence and performance of former candidates who have taken the KEY international exam, the majority of students had difficulties with some sub-skills during this test and in their performance in classes; It was observed that carrying out these types of activities helps to improve the students' oral expression skills, even more so if they are carried out in an enjoyable and motivating way. It is concluded that the lack of significant practice during the development of the A2 level preparation course at High Challenge Language Institute affects the oral competence of the students.

Sai-Hong Ignatius Ou,1 Xiuning Le,2 Misako Nagasaka,1 Thanyanan Reungwetwattana,3 Myung-Ju Ahn,4 Darren WT Lim,5 Edgardo S Santos,6 Elaine Shum,7 Sally CM Lau,7 Jii Bum Lee,8 Antonio Calles,9 Fengying Wu,10 Gilberto Lopes,11 Virote Sriuranpong,12 Junko Tanizaki,13 Hidehito Horinouchi,14 Marina C Garassino,15 Sanjay Popat,16 Benjamin Besse,17 Rafael Rosell,18 Ross A Soo19 1University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA; 2University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 4Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 5Duke-NUS School of medicine, National Cancer Center Singapore, Republic of Singapore; 6Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, 33431, USA; 7NYU Langone Perlmutter Cancer Center, NY, NY, USA; 8Yonsei Cancer Center Yonsei University, Seoul, Republic of Korea; 9Department of Medicine, Division of Medical Oncology, Early Drug Development and Phase I Unit, Hospital General Universitario Gregorio Marañón, Madrid, 28007, Spain; 10Shanghai Chest hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 11Department of Medicine, Division of Medical Oncology, Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine, Miami, FL, 33136, USA; 12Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; 13Department of Medicine, Kindai University School of Medicine, Osaka, Japan; 14Department of Thoracic Oncology, National Cancer Center Hospital Tokyo, Tokyo, Japan; 15Department of Medicine, Division of Medical Oncology-Hematology, University of Chicago Medicine, Chicago, IL, USA; 16Royal Marsden Hospital, London, Imperial College, London, UK; 17Gustave Roussy Cancer Campus, Villejuif, France; Paris-Saclay University, Orsay, France; 18Department of Hematology-Oncology, National University Cancer Institute, National University Hospital Singapore, Republic of Singapore; 19IOR, Quirón-Dexeus University Institute; ICO, Catalan Institute of Oncology; IGTP, Germans Trias i Pujol Research Institute, Barcelona, SpainCorrespondence: Sai-Hong Ignatius Ou, University of California School of Medicine, Department of Medicine, Division of Hematology-Oncology, Chao Family Comprehensive Cancer Center, 200 South Manchester Avenue, Suite 400, Orange, CA, 92868, USA, Tel +1 714-456-5153, Fax +1 714-456-2242, Email Siou@hs.uci.eduAbstract: The year 2024 is the 20th anniversary of the discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Since then, tremendous advances have been made in the treatment of NSCLC based on this discovery. Some of these studies have led to seismic changes in the concept of oncology research and spurred treatment advances beyond NSCLC, leading to a current true era of precision oncology for all solid tumors. We now routinely molecularly profile all tumor types and even plasma samples of patients with NSCLC for multiple actionable driver mutations, independent of patient clinical characteristics nor is profiling limited to the advanced incurable stage. We are increasingly monitoring treatment responses and detecting resistance to targeted therapy by using plasma genotyping. Furthermore, we are now profiling early-stage NSCLC for appropriate adjuvant targeted treatment leading to an eventual potential “cure” in early-stage EGFR+ NSCLC which have societal implication on implementing lung cancer screening in never-smokers as most EGFR+ NSCLC patients are never-smokers. All these advances were unfathomable in 2004 when the five papers that described “discoveries” of activating EGFR mutations (del19, L858R, exon 20 insertions, and “uncommon” mutations) were published. To commemorate this 20th anniversary, we assembled a global panel of thoracic medical oncology experts to select the top 20 papers (publications or congress presentation) from the 20 years since this seminal discovery with December 31, 2023 as the cutoff date for inclusion of papers to be voted on. Papers ranked 21 to 30 were considered “honorable mention” and also annotated. Our objective is that these 30 papers with their annotations about their impact and even all the ranked papers will serve as “syllabus” for the education of future thoracic oncology trainees. Finally, we mentioned potential practice-changing clinical trials to be reported. One of them, LAURA was published online on June 2, 2024 was not included in the list of papers to be voted on but will surely be highly ranked if this consensus survery is performed again on the 25th anniversay of the discovery EGFR mutations (i.e. top 25 papers on the 25 years since the discovery of activating EGFR mutations).Keywords: EGFR mutations, expert panel, top 20 papers, 20th anniversary, NSCLC

Julia Sabin,1 Elisa Salas,2 Jesús Martín-Martínez,3 Antonio Candeliere-Merlicco,4 Francisco Javier Barrero Hernández,5 Ana María Alonso Torres,6 José Luis Sánchez-Menoyo,7 Laura Borrega,8 María Rodríguez-Rodríguez,9 Montserrat Gómez-Gutiérrez,10 Sara Eichau,11 Miguel Ángel Hernández-Pérez,12 Carmen Calles,13 Eva Fernandez-Diaz,14 Olga Carmona,15 Aida Orviz,16 Ana López-Real,17 Pablo López-Muñoz,18 Amelia Mendoza Rodríguez,19 Eduardo Aguera-Morales,20 Jorge Maurino2 1Department of Neurology, Hospital Universitario Puerta de Hierro, Madrid, Spain; 2Medical Department, Roche Farma, Madrid, Spain; 3Department of Neurology, Hospital Universitario Miguel Servet, Zaragoza, Spain; 4Department of Neurology, Hospital Rafael Méndez, Lorca, Spain; 5Department of Neurology, Hospital Clínico Universitario San Cecilio, Granada, Spain; 6Department of Neurology, Hospital Regional Universitario de Málaga, Málaga, Spain; 7Department of Neurology, Hospital de Galdakao-Usansolo, Galdakao, Spain; 8Department of Neurology, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain; 9Department of Neurology, Hospital Universitario Lucus Augusti, Lugo, Spain; 10Department of Neurology, Hospital San Pedro de Alcántara, Cáceres, Spain; 11Department of Neurology, Hospital Universitario Virgen Macarena, Sevilla, Spain; 12Department of Neurology, Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain; 13Department of Neurology, Hospital Universitario Son Espases, Palma de Mallorca, Spain; 14Department of Neurology, Hospital Universitario de Albacete, Albacete, Spain; 15Department of Neurology, Fundació Salut Empordà, Figueres, Spain; 16Department of Neurology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; 17Department of Neurology, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; 18Department of Neurology, Hospital Arnau de Vilanova, Llíria, Spain; 19Department of Neurology, Complejo Asistencial de Segovia, Segovia, Spain; 20Department of Neurology, Hospital Universitario Reina Sofía, Córdoba, SpainCorrespondence: Jorge Maurino, Ribera del Loira 50, Madrid, 28042, Spain, Tel + 34 913 24 81 00, Email jorge.maurino@roche.comPurpose: Shared decision-making is critical in multiple sclerosis (MS) due to the uncertainty of the disease trajectory over time and the large number of treatment options with differing efficacy, safety and administration characteristics. The aim of this study was to assess patients’ decisional conflict regarding the choice of a disease-modifying therapy and its associated factors in patients with mid-stage relapsing-remitting multiple sclerosis (RRMS).Methods: A multicenter, non-interventional study was conducted. Adult patients with a diagnosis of RRMS (2017 revised McDonald criteria) and disease duration of 3 to 8 years were included. The level of uncertainty experienced by a patient when faced with making a treatment choice was assessed using the 4-item Decisional Conflict Scale. A battery of patient-reported and clinician-rated measures was administered to obtain information on symptom severity, illness perception, illness-related uncertainty, regret, MS knowledge, risk taking behavior, preferred role in the decision-making process, cognition, and self-management. Patients were recruited during routine follow-up visits and completed all questionnaires online using electronic tablets at the hospital. A multivariate logistic regression analysis was conducted.Results: A total of 201 patients were studied. Mean age (Standard deviation) was 38.7 (8.4) years and 74.1% were female. Median disease duration (Interquartile range) was 6.0 (4.0– 7.0) years. Median EDSS score was 1.0 (0– 2.0). Sixty-seven (33.3%) patients reported a decisional conflict. These patients had lower MS knowledge and more illness uncertainty, anxiety, depressive symptoms, fatigue, subjective symptom severity, a threatening illness perception, and poorer quality of life than their counterparts. Lack of decisional conflict was associated with MS knowledge (Odds ratio [OR]=1.195, 95% CI 1.045, 1.383, p=0.013), self-management (OR=1.049, 95% CI 1.013, 1.093, p=0.018), and regret after a healthcare decision (OR=0.860, 95% CI 0.756, 0.973, p=0.018) in the multivariate analysis.Conclusion: Decisional conflict regarding the selection of a disease-modifying therapy was a common phenomenon in patients with mid-stage RRMS. Identifying factors associated with decisional conflict may be useful to implement preventive strategies that help patients better understand their condition and strengthen their self-management resources.Keywords: multiple sclerosis, disease-modifying therapies, decision-making, decisional conflict, disease-related knowledge, self-management

Samples of Sr4Al6O12SO4 are obtained through a solid-state reaction of Al2O3, SrSO4, and SrCO3. The samples are then made into 1 and 4 cm pellets by compacting them at 100MPa and sintering them at 1400 °C for 4 h. The compound is analyzed using X-ray diffraction. Static immersion and wettability tests are carried out to evaluate corrosion resistance in contact with Al–Si. Corrosion tests are conducted by immersing the samples at 800, 900, and 1000 °C for 24, 50, and 100 h, while wettability is studied at 900, 1000, and 1100 °C for 2 h. Afterwards, the samples are subject to metallographic preparation. The samples are then analyzed using optical microscopy, scanning electron microscopy, and image analysis. In general, reaction products consisting of alumina, spinel, oxides, and sulfates are found. The contact angles obtained are between 124° and 135°. It is concluded that the Sr4Al6O12SO4 ceramic substrate is resistant to corrosion by the Al–Si alloy because of the slight thickness of the reaction products found in the samples (73 μm), considering the severe conditions of the experiment: 1000 °C and 100 h of isothermal temperature. Furthermore, Sr4Al6O12SO4 is not wettable by Al–Si alloys. These results suggest that the ceramic substrate could be used in the refractory industry, possibly as an additive to commercial refractory ceramics. For future work, it is recommended to carry out the same study with the aluminum–magnesium alloy and as an additive in commercial refractory ceramics.

The last consensus statement of the Spanish Society of Neurology’s Demyelinating Diseases Study Group on the treatment of multiple sclerosis (MS) was issued in 2016. Although many of the positions taken remain valid, there have been significant changes in the management and treatment of MS, both due to the approval of new drugs with different action mechanisms and due to the evolution of previously fixed concepts. This has enabled new approaches to specific situations such as pregnancy and vaccination, and the inclusion of new variables in clinical decision-making, such as the early use of high-efficacy disease-modifying therapies (DMT), consideration of the patient’s perspective, and the use of such novel technologies as remote monitoring.In the light of these changes, this updated consensus statement, developed according to the Delphi method, seeks to reflect the new paradigm in the management of patients with MS, based on the available scientific evidence and the clinical expertise of the participants.The most significant recommendations are that immunomodulatory DMT be started in patients with radiologically isolated syndrome with persistent radiological activity, that patient perspectives be considered, and that the term “lines of therapy” no longer be used in the classification of DMTs (> 90% consensus). Following diagnosis of MS, the first DMT should be selected according to the presence/absence of factors of poor prognosis (whether epidemiological, clinical, radiological, or biomarkers) for the occurrence of new relapses or progression of disability; high-efficacy DMTs may be considered from disease onset. Resumen: El último documento de consenso del Grupo de Estudio de Enfermedades Desmielinizantes de la Sociedad Española de Neurología sobre el tratamiento de la esclerosis múltiple (EM) data del año 2016. Aunque muchas consideraciones continúan todavía vigentes, desde entonces se han producido significativos cambios en el manejo y tratamiento de esta enfermedad motivados no sólo por la aprobación de nuevos fármacos con diferentes mecanismos de acción, sino también por la evolución de conceptos otrora consolidados. Esto ha permitido abordar situaciones especiales como el embarazo y la vacunación desde otra perspectiva e incluir nuevas variables en la toma de decisiones en práctica clínica, como plantear tratamiento modificador de la enfermedad (TME) de alta eficacia en fases tempranas, considerar la perspectiva del paciente y utilizar nuevas tecnologías como monitorización remota.Estos cambios han motivado la presente actualización del consenso mediante metodología Delphi, con el objetivo de reflejar el nuevo paradigma de manejo del paciente con EM basándose en la evidencia científica y experiencia clínica de los participantes.Entre las principales conclusiones destacan como recomendaciones: iniciar TME inmunomodulador en el síndrome radiológico aislado con actividad radiológica persistente, evaluar la perspectiva del paciente y abandonar la terminología “líneas de tratamiento” en la clasificación de los TME (consenso mayor del 90%). Tras el diagnóstico de EM, la elección del primer TME debería considerar la presencia/ausencia de factores de mal pronóstico (epidemiológicos, clínicos, radiológicos y biomarcadores) para la aparición de nuevos brotes o progresión de discapacidad, pudiendo plantear desde el inicio TME de alta eficacia.

Resumen: El último documento de consenso del Grupo de Estudio de Enfermedades Desmielinizantes de la Sociedad Española de Neurología sobre el tratamiento de la esclerosis múltiple (EM) data del año 2016. Aunque muchas consideraciones continúan todavía vigentes, desde entonces se han producido cambios significativos en el manejo y tratamiento de esta enfermedad, motivados no solo por la aprobación de nuevos fármacos con diferentes mecanismos de acción, sino también por la evolución de conceptos otrora consolidados. Esto ha permitido abordar situaciones especiales como el embarazo y la vacunación desde otra perspectiva, e incluir nuevas variables en la toma de decisiones en práctica clínica, como plantear tratamiento modificador de la enfermedad (TME) de alta eficacia en fases tempranas, considerar la perspectiva del paciente y utilizar nuevas tecnologías como monitorización remota.Estos cambios han motivado la presente actualización del consenso mediante metodología Delphi, con el objetivo de reflejar el nuevo paradigma de manejo del paciente con EM basándose en la evidencia científica y la experiencia clínica de los participantes.Entre las principales conclusiones destacan como recomendaciones: iniciar TME inmunomodulador en el síndrome radiológico aislado con actividad radiológica persistente, evaluar la perspectiva del paciente y abandonar la terminología «líneas de tratamiento» en la clasificación de los TME (consenso mayor del 90%). Tras el diagnóstico de EM la elección del primer TME debería considerar la presencia/ausencia de factores de mal pronóstico (epidemiológicos, clínicos, radiológicos y biomarcadores) para la aparición de nuevos brotes o progresión de discapacidad, pudiendo plantear desde el inicio TME de alta eficacia. Abstract: The last consensus statement of the Spanish Society of Neurology's Demyelinating Diseases Study Group on the treatment of multiple sclerosis (MS) was issued in 2016. Although many of the positions taken remain valid, there have been significant changes in the management and treatment of MS, both due to the approval of new drugs with different action mechanisms and due to the evolution of previously fixed concepts. This has enabled new approaches to specific situations such as pregnancy and vaccination, and the inclusion of new variables in clinical decision-making, such as the early use of high-efficacy disease-modifying therapies (DMT), consideration of the patient's perspective, and the use of such novel technologies as remote monitoring.In the light of these changes, this updated consensus statement, developed according to the Delphi method, seeks to reflect the new paradigm in the management of patients with MS, based on the available scientific evidence and the clinical expertise of the participants.The most significant recommendations are that immunomodulatory DMT be started in patients with radiologically isolated syndrome with persistent radiological activity, that patient perspectives be considered, and that the term “lines of therapy” no longer be used in the classification of DMTs (> 90% consensus). Following diagnosis of MS, the first DMT should be selected according to the presence/absence of factors of poor prognosis (whether epidemiological, clinical, radiological, or biomarkers) for the occurrence of new relapses or progression of disability; high-efficacy DMTs may be considered from disease onset.

Adolescence is established as an important stage in the human being, we try to show how positive or negative this stage can be in the development of an adequate environment, elucidating the benefits or consequences that can affect the psychomotor devel-opment of a person. Adolescence is the time when the personality of an individual is defined, influenced by various factors that can help the subject to develop adequately in society, as well as fac-tors that can affect the subject conditioning him/her to an environ-ment that is not favorable for his/her development. Both physical and psychological changes are mentioned, as well as hormonal factors which play an important role in development. It is intend-ed to demonstrate the hormonal mechanisms that condition the changes in the development of the human being

Monoclonal antibody therapeutics to treat coronavirus disease (COVID-19) have been authorized by the US Food and Drug Administration under Emergency Use Authorization (EUA). Many barriers exist when deploying a novel therapeutic during an ongoing pandemic, and it is critical to assess the needs of incorporating monoclonal antibody infusions into pandemic response activities. We examined the monoclonal antibody infusion site process during the COVID-19 pandemic and conducted a descriptive analysis using data from 3 sites at medical centers in the United States supported by the National Disaster Medical System. Monoclonal antibody implementation success factors included engagement with local medical providers, therapy batch preparation, placing the infusion center in proximity to emergency services, and creating procedures resilient to EUA changes. Infusion process challenges included confirming patient severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity, strained staff, scheduling, and pharmacy coordination. Infusion sites are effective when integrated into pre-existing pandemic response ecosystems and can be implemented with limited staff and physical resources.

Antecedentes: Los sistemas agroforestales tradicionales (SAF) son capaces de mantener la diversidad vegetal nativa mediante diferentes prácticas campesinas. Preguntas: ¿En qué medida los SAF mantienen la composición, diversidad y abundancia de plantas perennes? ¿Qué variaciones hay entre distintos tipos de vegetación? Especies de estudio: Plantas perennes presentes en SAF asociados a bosques de cactáceas columnares, bosques templados, bosques espinosos, matorrales rosetófilos y selvas bajas caducifolias. Sitio y años de estudio: 13 comunidades del Valle de Tehuacán-Cuicatlán, en Oaxaca y Puebla, México. Revisión de trabajos y datos propios publicados entre 2010 y 2020. Métodos: Evaluamos la composición florística, capacidad de conservación de diversidad y abundancia de individuos mediante un análisis de redundancia, la estimación de números efectivos de especies y modelos lineales generalizados en 30 SAF y 30 muestreos de la vegetación silvestre de la que derivan. Resultados: Los SAF analizados son capaces de mantener 68 % de la riqueza de especies y 34 % de los individuos de plantas perennes presentes en la vegetación silvestre circundante. Los SAF y la vegetación silvestre son semejantes en términos de composición y diversidad de especies, aunque en el caso del bosque espinoso hay una clara reducción del número de especies y un cambio en la composición. La abundancia de individuos es notoriamente menor en los SAF. Conclusiones: Los SAF son una alternativa capaz de resguardar una parte significativa de la diversidad vegetal nativa. La justa valoración y la promoción del manejo campesino agroecológico mediante SAF debe ser considerado en las políticas de conservación.

Los telares constituyen uno de los principales instrumentos para la producción textil en la Antigüedad. No obstante, su localización en el registro arqueológico es escasa y limitada. Los telares verticales de pesas son la tipología más conocida, pero no la única. Excepcionalmente, se encuentran en el registro arqueológico evidencias materiales de telares de bandas para el desarrollo de estrechas cenefas que, por lo general, presentan ricas decoraciones. Una de las principales problemáticas ha sido la identificación de estas piezas, la definición de su funcionalidad textil y la confusión existente entre los distintos tipos de telares de bandas. En consecuencia, no solo son difíciles de encontrar arqueológicamente, sino que a menudo no han sido reconocidas como instrumental textil. En este trabajo, aportamos un acercamiento a la tecnología de los telares de bandas en Hispania a partir de un nuevo hallazgo: un telar de rejilla o lizo de marco procedente de un contexto funerario recientemente intervenido en Augusta Emerita (Mérida, Badajoz). Además del análisis de la pieza, planteamos un estudio contextual que permita hacer apreciaciones cronológicas. A ello se le une el estudio antropológico del difunto varón. Esto nos ayuda a plantear y discutir interesantes apreciaciones de género respecto a la configuración social del artesanado textil. Del mismo modo, recogemos un estado actual de la cuestión sobre la tecnología del telar de lizo de marco gracias a una revisión de todas las evidencias encontradas hasta la fecha a lo largo del Imperio. Con este artículo, esperamos ahondar en este tipo de tecnologías textiles, visibilizarlas y dar a conocer su materialización en el registro arqueológico.

Through the powder metallurgy technique, alloys of the eutectic composition of the Zn-Al system were manufactured (22.3 wt.%Al), reinforced with Ag additions (0.5, 1, 2.5, 5 wt.%), with subsequent annealing heat treatment at three different temperatures; 100, 150 and 200°C for 1 hr. X-ray diffraction, optical microscopy and mechanical tests were performed on the resulting samples. The addition of Ag favors the formation of alpha and beta compounds with Al and Zn respectively, which improves the compressive strength of the alloy. However, with the presence of Ag the hardness is decreased. On the other hand, the application of an annealing heat treatment, shows no significant effect on the evaluated properties of the alloy. The microstructure of the alloys resulted in the presence of very small grains smaller than 1 mm and with rounded morphology.

Introduction: Clear cell sarcoma (CCS) is a rare and aggressive soft tissue sarcoma. CCS is characterized by the translocation t(12;22) (q13;q12), involving the fusion of EWSR1 and ATF1 genes, and less frequently the fusion gene EWSR1-CREB1. Usually, CCSs are considered poorly responsive to conventional chemotherapy. However, trabectedin has shown activity against translocation-related sarcomas. Furthermore, preclinical results suggest that trabectedin is a promising antitumor agent for CCS, potentially inducing melanocytic differentiation. Case Presentation: We report the case of a challenging anatomopathological diagnosis in a patient with an aggressive metastatic CCS. Following the diagnosis of CCS, the patient experienced a clinical and radiological tumor response to trabectedin after four lines of treatment. Conclusion: This is a novel report of CCS treated with trabectedin that resulted in a partial response and suggests the need for further research on trabectedin as a therapeutic option for CCS.

Basic science courses, such as physics, are fundamental to precollege studies. For instance, in different engineering applications, electricity and magnetism require comprehending subjects such as electrical circuits and power electronics. However, abstract concepts such as electric or magnetic fields are often difficult to explain without visual tools. Computer programs designed for learning physics fundamentals are useful in this area because they allow the visualization, interaction and reinforcement of main concepts in a better way than using only blackboard. In this work, an interactive MATLAB based program to visualize a magnetic field in 3D was presented. The measurements were sampled by a computer-controlled Cartesian robot with a Hall effect sensor. The magnetic field was generated by an energized electromagnet to show the relationship between electricity and magnetism. The designed graphical user interface aims to stimulate interest in electromagnetism in precollege students.

Introduction: RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of RET fusions remains a difficult challenge. Most guidelines encourage the upfront use of next-generation sequencing (NGS), or alternatively, fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction (RT-PCR) when NGS is not possible or available. Taken together, the suboptimal performance of single-analyte assays to detect RET fusions, although consistent with the notion of encouraging universal NGS, is currently widening some of the clinical practice gaps in the implementation of predictive biomarkers in patients with advanced NSCLC. Methods: This situation prompted us to evaluate several RET assays in a large multicenter cohort of RET fusion–positive NSCLC (n = 38) to obtain real-world data. In addition to RNA-based NGS (the criterion standard method), all positive specimens underwent break-apart RET FISH with two different assays and were also tested by an RT-PCR assay. Results: The most common RET partners were KIF5B (78.9%), followed by CCDC6 (15.8%). The two RET NGS-positive but FISH-negative samples contained a KIF5B(15)-RET(12) fusion. The three RET fusions not identified with RT-PCR were AKAP13(35)-RET(12), KIF5B(24)-RET(9) and KIF5B(24)-RET(11). All three false-negative RT-PCR cases were FISH-positive, exhibited a typical break-apart pattern, and contained a very high number of positive tumor cells with both FISH assays. Signet ring cells, psammoma bodies, and pleomorphic features were frequently observed (in 34.2%, 39.5%, and 39.5% of tumors, respectively). Conclusions: In-depth knowledge of the advantages and disadvantages of the different RET testing methodologies could help clinical and molecular tumor boards implement and maintain sensible algorithms for the rapid and effective detection of RET fusions in patients with NSCLC. The likelihood of RET false-negative results with both FISH and RT-PCR reinforces the need for upfront NGS in patients with NSCLC.

Antecedentes: Los sistemas agrosilvícolas (SA) integran diversidad agrícola, forestal y cultural. En regiones costeras de México han sido poco estudiados, particularmente los manejados por mixtecos y afromexicanos de la costa de Oaxaca. Preguntas: ¿Qué SA se encuentran en comunidades mixtecas y afromexicanas?, ¿Cuáles son las especies útiles, formas de manejo, prácticas agrícolas y agroforestales de los SA? Especies de estudio: Diversas. Sitio y años de estudio: Santa María Chicometepec, Cerro de la Esperanza, Collantes, Santa Elena Comaltepec, San Agustín Chayuco, Santiago Tetepec, Oaxaca. Octubre 2021 a octubre 2022. Métodos: Se realizaron 60 entrevistas semiestructuradas a especialistas locales en tres comunidades mixtecas y tres afromexicanas. Se preguntó acerca de especies útiles, sistemas agrosilvícolas, prácticas agrícolas, agroforestales y de manejo. Se realizaron recorridos y colectas de ejemplares de herbario. Se describió cada sistema por sus prácticas agroforestales y de manejo. Se registró el número de especies útiles por categoría de uso y grupo cultural. Resultados: Se documentaron y describieron seis SA: milpa, potreros, solares, acahuales, piñal y cocotal. Las prácticas agrícolas en comunidades mixtecas se realizan con herramientas e insumos básicos y la producción tiene un fin de autoconsumo y venta local, mientras que en comunidades afromexicanas son tecnificadas y su destino es la venta regional. Linderos y árboles aislados fueron las prácticas agroforestales más comunes. Conclusiones: Mixtecos y Afromexicanos comparten SA, formas de manejo y prácticas agroforestales, difieren en las prácticas agrícolas. En los SA se conservan principalmente especies comestibles y maderables. El número de especies útiles es similar en comunidades mixtecas y afromexicanas.